It has been a while since we've seen demand exceed supply in the cannabis space, but Missouri's soaring recreational weed market is now facing a product shortage.
It was a regular occurrence when new states opened recreational sales, but with so much talk about oversupply across markets, that feels like a time long past. Missouri's legalized adult-use cannabis market has been off to a red-hot start and we are seeing inventory depletions at rates far faster than even large operators there can handle.
The Midwestern state launched its recreational weed market on Feb. 3, and is on pace to surpass $1 billion in sales during its first year online. Strong demand from local and out-of-state customers has exceeded expectations for the state's legalized weed sales, resulting in product shortages and higher wholesale prices.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Near the Kansas border, Missouri cannabis retailers are seeing foot traffic increase ninefold, and many Illinois residents are crossing the Mississippi River to purchase cheaper cannabis in St. Louis. The product shortages and pricing issues in Missouri's recreational weed market will be corrected as more capacity comes online.
As long-time industry participants, we hope that history doesn't repeat itself and capacity builds are aligned with Missouri's demand levels.
Legal cannabis sales surpass $33.5 billion
The legal cannabis industry continues its headline growth, with industry publication Marijuana Business Daily projecting 2023 sales of $33.5 billion. The projections are a $4 billion increase from 2022, and by 2028 legal cannabis could see sales close to $57 billion.
Cannabis sales from this year will surpass the money spent on craft beer, chocolate, chicken eggs and topical pain relief. With the number of licensed U.S. marijuana businesses now exceeding 165,000, the cannabis industry is expected to inject $100.8 billion into the overall economy this year.
For context, Poseidon started investing in cannabis with outside capital in 2014, when legal recreational sales first began. It is amazing to reflect on that time, having watched an industry grow from a modest medical market with $0 in recreational sales to $33.5 billion nine years later. The industry did this with no federal support, no broad banking access, a pandemic, and a two-plus-year capital crunch with significant price compression in many markets.
The throughline is that there is strong demand for legal cannabis. Though messy and frustrating at times, legalization is working. Imagine how much more is on the horizon as regulatory progress continues.
Curaleaf renews New Jersey recreational license
Most of the regulatory action in cannabis is at the state level, and we often talk about the positives of new states opening or the challenges impairing market growth. Late last week was a unique situation as the New Jersey Cannabis Regulatory Commission (CRC) surprisingly decided not to renew material recreational licenses belonging to publicly traded marijuana stock Curaleaf Holdings (CURLF).
These actions by the New Jersey CRC board essentially stripped Curaleaf of its ability to serve recreational consumers in the state. Citing the closure of a cultivation facility in Bellmawr and interference with unionizing efforts, the decision would have impacted the company's ability to grow and forced it to shut down dispensaries in Edgewater Park and Bellmawr.
We were shocked and very concerned about how this decision was made and the potential fallout. Thankfully, cannabis industry operators are well-versed in politics, and we were pleased to see Curaleaf respond swiftly, professionally, and with a time-tested tool of democracy – peaceful protest. The CRC quickly reconvened this week and course corrected by providing the renewals to Curaleaf under certain conditions.
"As we said after the decision, this was an arbitrary decision without legal merit, and that's been demonstrated with the board's new decision today," said Matt Darin, CEO of Curaleaf, said in a press release.
New initiative proposes the removal of the 280E tax
Representative Earl Blumenauer (D-Oregon) continues to be one of our industry's longest-running champions, trying to effect real change in Washington D.C.
It is 4/20 week, our industry's primary holiday and politicians are capitalizing on the attention. We are proponents of removing the 280E tax, which is the objective of the Small Business Equity Tax Act, which Blumenauer refiled this week. Representative Nancy Mace (R-South Carolina) originally filed the bill late last year and will co-sponsor it this year alongside Blumenauer and Representatives Barbara Lee (D-California) and Dave Joyce (R-Ohio).
"State-legal cannabis businesses are denied equal treatment under 280E," Blumenauer said in a press release. "They cannot fully deduct the cost of doing business which means they pay two or three times as much as a similar non-cannabis business.
"This grotesquely unfair treatment incentivizes people to cut corners. If Congress wants to get serious about supporting small businesses and ending the illicit cannabis market, it is common sense that we allow legal cannabis operations to deduct business expenses, just like any other industry."
Our industry would be far healthier from the smallest to the largest operators when 280E is finally repealed and replaced. Note that we are not proposing or supporting a 21% federal tax rate. Sadly, D.C. does not realize the job destruction that is happening to small operators in cannabis due to this tax. Please bring this bill to a vote in Congress and make a real difference for the cannabis industry.
-
Visa Is the Worst Dow Stock Wednesday. Here's WhyVisa stock is down sharply Wednesday after the credit card company came up short of revenue expectations for its fiscal Q3.
-
Another Analyst Moves to the Sidelines on Tesla Stock After EarningsTesla stock is spiraling Wednesday after the EV maker's big earnings miss and Wall Street has been quick to weigh in. Here's what you need to know.
-
Will Cannabis Be Impacted By Kevin McCarthy's Ouster?: This Week in Cannabis InvestingA cannabis banking bill could feel the reverberations from the removal of McCarthy as speaker of the House.
-
Green Thumb Industries is a Cannabis Cash Cow: This Week in Cannabis InvestingGreen Thumb Industries reported solid cash flow generation in the first quarter despite continued price compression.
-
SAFE Banking Act Gets New Life: This Week in Cannabis InvestingA bipartisan effort has given the SAFE Banking Act, which helps improve cannabis companies' access to finance, a shot to reach the Senate floor.
-
Delta-8 Restricted in Kentucky: This Week in Cannabis InvestingKentucky lawmakers passed a bipartisan bill to regulate Delta-8 THC, a psychoactive cannabinoid.
-
Delta-8 THCO and Delta-9 THCO Classified as Schedule I Drugs: This Week in Cannabis InvestingThe Drug Enforcement Agency said delta cannabinoids, including Delta-8 THCO and Delta-9 THCO, are synthetically derived from hemp, and, therefore, are not considered hemp.
-
Marijuana Legalization Efforts Gain Traction: This Week in Cannabis InvestingMarijuana Legalization Efforts Gain Traction: This Week in Cannabis Investing
-
Jay-Z and TPCO Restructure Partnership: This Week in Cannabis InvestingConsumer-focused cannabis company TPCO will see significant cost savings thanks to a new deal with Chief Visionary Officer Jay-Z.
-
Lawmakers Delay SAFE Banking Act: This Week in Cannabis InvestingThe SAFE Banking Act is at risk of not passing during the lame-duck session in Congress, sparking volatility in marijuana stocks.
